Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tandem Diabetes Care, Inc. (NASDAQ: TNDM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tandem Diabetes Care is a global insulin delivery and diabetes technology company whose common stock is registered under Section 12(b) of the Exchange Act and listed on the NASDAQ Global Market under the symbol TNDM.
Through this page, users can review current reports on Form 8-K that document material events such as quarterly earnings announcements, regulatory clearances, and board of director changes. Recent 8-K filings referenced by the company include reports on financial results for quarters ended during 2025 and the appointment of a new independent director to the board, along with related committee assignments and compensation details. Other 8-K filings describe FDA 510(k) clearance for the SteadiSet infusion set and similar operational milestones.
In addition to 8-Ks, Tandem Diabetes Care files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed information on its insulin delivery systems, financial condition, risk factors, and business strategy. These filings are important for understanding how the company’s pump portfolio, infusion sets, mobile applications, and cloud-based platforms contribute to its overall operations and financial results.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify information on revenue drivers, regulatory developments, and governance matters. The platform also surfaces insider transaction reports on Form 4 when available, allowing investors to monitor share transactions by directors and officers. Real-time updates from the SEC’s EDGAR system ensure that new Tandem Diabetes Care filings appear promptly, while AI-generated explanations make complex regulatory language more accessible.
Leigh A. Vosseller, EVP & Chief Financial Officer of Tandem Diabetes Care, Inc. (TNDM), reported multiple transactions on 08/15/2025 related to vested restricted stock units (RSUs) and tax-withholding events. The filing shows two RSU vesting events that resulted in the acquisition of 1,503 and 1,495 shares each (total 2,998 shares) at $0 price upon vesting, increasing her direct holdings. The report also records share withholdings to satisfy tax obligations: 538 and 535 shares withheld at $10.82 per share. Following the transactions, total directly held common stock positions reported are 4,509 and 10,469 shares tied to two RSU awards, and 35,723–36,258 shares in various lines; additionally, 25,580 shares are held indirectly in the Leigh A. Vosseller Trust. The form was signed by an attorney-in-fact on 08/19/2025.
Tandem Diabetes Care insider Shannon M. Hansen reported multiple transactions on 08/15/2025 related to restricted stock units (RSUs) and common stock. The filing shows vesting-driven acquisitions: 531, 1,437 and 1,097 RSUs converted into common stock (total underlying 3,065 shares added to direct holdings) and corresponding increases in direct common stock ownership to a reported 7,677 shares of derivative-backed common stock and 19,102 shares of direct common stock at various steps. Several entries show shares withheld to satisfy tax withholding at $10.82 per share; no open-market sales were reported. The securities held indirectly are in the Shannon M. Hansen Trust.
Elizabeth A. Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care, reported multiple transactions on 08/15/2025 affecting her holdings of TNDM common stock. She acquired 1,503 shares (RSU vesting) and an additional 1,097 shares (RSU vesting), both reported as acquisitions at $0 per share. To satisfy tax withholding on vesting, 805 and 588 shares were withheld and disposed at $10.82 per share; no shares were sold on the open market. She directly beneficially owns 4,509 shares from vested RSUs and 7,677 shares from other RSUs per the table, and indirectly holds 22,949 shares through The Gasser Family Trust, where she is a co-trustee.
John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported a non-derivative purchase of 10,000 shares on 08/11/2025. The filing states the trades executed at prices ranging from $10.19 to $10.33, with a weighted average purchase price of $10.2318. Following the reported transaction, the reporting person beneficially owned 106,327 shares.
The Form 4 identifies the filing as by one reporting person and includes an explanatory note that full details of the multiple trades (number of shares per trade and individual prices) will be provided upon request. The form is signed by Rachel Malina as attorney-in-fact for John F. Sheridan.
Diabetes Care Inc EVP & Chief Financial Officer Leigh Vosseller reported an open-market purchase of common stock on August 8, 2025. A trust bearing her name bought 13,720 shares at a weighted average price of $10.8895 per share, through multiple trades between $10.86 and $10.90.
After this transaction, the trust holds 25,580 shares indirectly, while Vosseller also holds 33,798 shares directly. The filing notes that the securities are held by the Leigh A. Vosseller Trust, for which she serves as trustee.
Tandem Diabetes Care (NASDAQ:TNDM) filed a routine Form 4 reporting Chief Technology Officer Rick Carpenter’s latest equity transaction.
On June 16 2025, Carpenter acquired 406 common shares through the vesting of previously granted restricted stock units (RSUs) at a stated price of $0. To cover statutory tax withholding, 207 shares were automatically withheld by the company and disposed of at $20.76 per share. Following the transactions, Carpenter directly owns 21,219 shares of Tandem Diabetes Care common stock.
The filing indicates these transfers were executed under the company’s 2013 Stock Incentive Plan and do not involve open-market purchases or sales. No additional derivative positions were reported beyond the RSU conversion.